X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs VENUS REMEDIES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA VENUS REMEDIES AUROBINDO PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 16.0 -889.3 - View Chart
P/BV x 4.1 0.3 1,577.1% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
VENUS REMEDIES
Mar-16
AUROBINDO PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs895218 410.6%   
Low Rs62282 757.6%   
Sales per share (Unadj.) Rs254.6365.6 69.6%  
Earnings per share (Unadj.) Rs39.31.5 2,643.1%  
Cash flow per share (Unadj.) Rs46.637.9 122.8%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.0382.5 41.8%  
Shares outstanding (eoy) m585.8811.44 5,121.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.00.4 726.0%   
Avg P/E ratio x19.3101.0 19.1%  
P/CF ratio (eoy) x16.34.0 411.5%  
Price / Book Value ratio x4.70.4 1,208.9%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,3901,717 25,888.2%   
No. of employees `00014.01.0 1,370.8%   
Total wages/salary Rs m17,678324 5,449.3%   
Avg. sales/employee Rs Th10,667.84,100.7 260.1%   
Avg. wages/employee Rs Th1,264.3318.0 397.5%   
Avg. net profit/employee Rs Th1,645.816.7 9,874.9%   
INCOME DATA
Net Sales Rs m149,1574,183 3,566.0%  
Other income Rs m1,15920 5,765.7%   
Total revenues Rs m150,3164,203 3,576.6%   
Gross profit Rs m34,343812 4,231.5%  
Depreciation Rs m4,276417 1,026.0%   
Interest Rs m667380 175.7%   
Profit before tax Rs m30,55835 87,060.4%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,59718 41,969.6%   
Profit after tax Rs m23,01217 135,364.1%  
Gross profit margin %23.019.4 118.7%  
Effective tax rate %24.951.6 48.2%   
Net profit margin %15.40.4 3,795.9%  
BALANCE SHEET DATA
Current assets Rs m92,0622,771 3,322.7%   
Current liabilities Rs m66,2231,931 3,428.8%   
Net working cap to sales %17.320.1 86.3%  
Current ratio x1.41.4 96.9%  
Inventory Days Days106125 84.7%  
Debtors Days Days6854 125.9%  
Net fixed assets Rs m62,9195,328 1,180.8%   
Share capital Rs m586114 512.2%   
"Free" reserves Rs m93,1334,177 2,229.6%   
Net worth Rs m93,7194,376 2,141.5%   
Long term debt Rs m1,8141,911 94.9%   
Total assets Rs m162,4948,428 1,928.0%  
Interest coverage x46.81.1 4,284.1%   
Debt to equity ratio x00.4 4.4%  
Sales to assets ratio x0.90.5 185.0%   
Return on assets %14.64.7 309.5%  
Return on equity %24.60.4 6,320.9%  
Return on capital %32.76.6 496.1%  
Exports to sales %00-   
Imports to sales %020.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA858 0.0%   
Fx inflow Rs m75,8380-   
Fx outflow Rs m30,224858 3,521.4%   
Net fx Rs m45,613-858 -5,314.4%   
CASH FLOW
From Operations Rs m32,786469 6,993.6%  
From Investments Rs m-17,87029 -61,200.0%  
From Financial Activity Rs m-19,153-464 4,132.2%  
Net Cashflow Rs m-4,23935 -12,286.1%  

Share Holding

Indian Promoters % 54.1 32.9 164.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.2 4,416.7%  
FIIs % 27.7 0.6 4,775.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 66.4 15.4%  
Shareholders   69,601 20,121 345.9%  
Pledged promoter(s) holding % 8.6 36.4 23.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ORCHID PHARMA LTD  DISHMAN PHARMA  TTK HEALTHCARE  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex & Nifty Open at Record Highs; Banking & PSU Stocks Rally(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.46% while the Hang Seng is up 0.28%. The Shanghai Composite is trading up by 0.43%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 18, 2018 09:59 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS